Another study further supporting the oncogenic potential of GR signaling revealed that GR activation can drive cancer cells into a reversible dormant state, characterized by resistance to multiple chemotherapeutic agents and increased sensitivity to inhibitors of the insulin-like growth factor 1 receptor (IGF1R)-mediated survival pathway [16]. The gene discussed is NR3C1; the disease is cancer.